Open AccessTransglucosidase improves the bowel movements in type 2 diabetes mellitus patients: A preliminary randomized double‐blind, placebo‐controlled study
Author(s) -
Shimozato Akihiro,
Sasaki Makoto,
Ogasawara Naotaka,
Funaki Yasushi,
Ebi Masahide,
Goto Chiho,
Koikeda Satoshi,
Joh Takashi,
Kasugai Kunio
Publication year - 2017
Publication title -
ueg journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.667
H-Index - 35
eISSN - 2050-6414
pISSN - 2050-6406
DOI - 10.1177/2050640617692268
Subject(s) - gastroenterology , medicine , placebo , feces , bacteroides , gut flora , dysbiosis , microbiology and biotechnology , immunology , biology , bacteria , pathology , disease , genetics , alternative medicine
Background Recent studies have highlighted the relationship between gut microbiota and bowel movements. Objective We aimed to evaluate transglucosidase treatment efficacy for bowel movements in patients with type 2 diabetes mellitus and to clarify the relationship between bowel movements, dietary habits, gut microbiota and fecal short‐chain fatty acids. Methods In this randomized double‐blind, placebo‐controlled study, 66 patients received placebo or transglucosidase (300 or 900 mg/day) orally, for 12 weeks. Fecal bacterial communities and short‐chain fatty acids were analyzed before and after the treatment. Results Transglucosidase treatment significantly ( p < 0.05) affected fecal microbiota ( Prevotella spp., Bacteroides spp., Bifidobacterium spp., and Clostridium subcluster XIVa) and fecal short‐chain fatty acid (acetate, valerate, succinate and lactate) content. Clostridium cluster IV, Clostridium subcluster XIVa, Clostridium cluster XVIII and fecal pH increased significantly and order Lactobacillales decreased in patients with bowel movement disorder compared with controls. Transglucosidase treatment significantly improved bowel movements compared with placebo treatment (46.2%, 95% confidence interval: 19.2–74.9% vs . 0%, 95% confidence interval: 0–33.6%, p < 0.05). This effect was not observed in patients without bowel movement disorder. Conclusion Patients with bowel movement disorder suffer from gut dysbiosis. Transglucosidase treatment alleviates bowel movement disorder symptoms in type 2 diabetes mellitus patients by increasing fecal acetate level.